Literature DB >> 16548717

Ryan White CARE Act Title II survey: services for HIV-positive substance users.

Carol Tobias1, Starr Wood, Mari-Lynn Drainoni.   

Abstract

A national survey was conducted among Ryan White CARE Act-funded providers to determine what types of services are specifically provided for HIV-positive substance users through Title II within the context of the overall delivery system for substance abuse treatment services. There was an 87% return rate on questionnaires representing 47 states. Only 18 of the 47 states reported funding some form of substance abuse services. The results show (1) the types of substance abuse services funded under Title II, (2) what special populations are served by those programs, (3) additional funding sources utilized by those programs, (4) the common systemic barriers to care, (5) the greatest programmatic barriers to care, and (6) gaps in knowledge about unmet needs for HIV-positive substance users. Some states have been quite innovative in targeting resources to support HIV-positive substance users while others report less activity. Although design and implementation of innovative programs for HIVpositive substance users rests with service providers, state agencies responsible for Title II planning are in the best position to identify system strengths and weaknesses.

Mesh:

Year:  2006        PMID: 16548717     DOI: 10.1089/apc.2006.20.205

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  2 in total

1.  Perceived discrimination among severely disadvantaged people with HIV infection.

Authors:  Nancy Sohler; Xuan Li; Chinazo Cunningham
Journal:  Public Health Rep       Date:  2007 May-Jun       Impact factor: 2.792

2.  Quality of care for HIV infection provided by Ryan White Program-supported versus Non-Ryan White Program-supported facilities.

Authors:  Patrick S Sullivan; Maxine Denniston; Eve Mokotoff; Susan Buskin; Stephanie Broyles; A D McNaghten
Journal:  PLoS One       Date:  2008-09-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.